Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FRANCISCO A KERDEL

Allopathic & Osteopathic Physicians Dermatology

NPI
1144258724
CMS profile
188421
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$373,100.46

468 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 10 of 10; records 451–468 of 468 matching records. This page contains 18 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FRANCISCO A KERDEL

NPI 1144258724 · CMS profile ID 188421

Allopathic & Osteopathic Physicians / Dermatology

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 10 of 10; records 451–468 of 468 matching records. This page contains 18 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144258724?year=2019&recipient=provider&page=10#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FRANCISCO A KERDEL, NPI 1144258724, CMS profile ID 188421. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 10 of 10; records 451–468 of 468 matching records. This page contains 18 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144258724?year=2019&recipient=provider&page=10#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). FRANCISCO A KERDEL, NPI 1144258724, CMS profile ID 188421. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 10 of 10; records 451–468 of 468 matching records. This page contains 18 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144258724?year=2019&recipient=provider&page=10#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
FRANCISCO A KERDEL, NPI 1144258724, CMS profile ID 188421, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 10 of 10; records 451–468 of 468 matching records. This page contains 18 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1144258724?year=2019&recipient=provider&page=10#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

468 matching records · $373,100.46 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 468 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 451–468 of 468.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Mayne Pharma Inc. $25.7801/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705502853 CMS
UCB, Inc. $3,200.0001/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688380711 CMS
UCB, Inc. $17.6101/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688251521 CMS
Celgene Corporation $125.0201/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672825333 CMS
Celgene Corporation $3,000.0001/09/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672832129 CMS
Celgene Corporation $547.0001/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672833053 CMS
AbbVie, Inc. $22.9501/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648028109 CMS
TARO PHARMACEUTICALS USA, INC. $24.5501/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704149105 CMS
Novartis Pharmaceuticals Corporation $2.2001/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659599717 CMS
Novartis Pharmaceuticals Corporation $208.7601/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659599745 CMS
Novartis Pharmaceuticals Corporation $206.6301/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659599747 CMS
Novartis Pharmaceuticals Corporation $7,040.0001/05/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659599749 CMS
Novartis Pharmaceuticals Corporation $90.9101/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659599751 CMS
Novartis Pharmaceuticals Corporation $121.7201/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659599753 CMS
Novartis Pharmaceuticals Corporation $34.0001/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659599755 CMS
Novartis Pharmaceuticals Corporation $426.9901/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659599783 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $14.8701/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684586957 CMS
LEO Pharma Inc. $19.1501/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687263777 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $373,100.46 468
PY2020 $160,990.25 237
PY2021 $194,736.58 294
PY2022 $316,754.27 374
PY2023 $324,609.32 355
PY2024 $347,073.09 411
PY2025 $336,883.66 433

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $336,886.17 74
PY2024 Recipient $199,350.00 1
PY2024 Principal investigator $649,461.93 118
PY2023 Recipient $4,200.00 1
PY2023 Principal investigator $362,191.95 50
PY2022 Recipient $38.00 1
PY2022 Principal investigator $212,855.61 51
PY2021 Recipient $66,875.00 1
PY2021 Principal investigator $309,055.10 69
PY2020 Recipient $592,927.15 7
PY2020 Principal investigator $668,650.57 78
PY2019 Recipient $27,841.04 7
PY2019 Principal investigator $492,794.35 62

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

74 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $665.04 12/31/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC DERMATOLOGY CENTER
A Phase 4 Multicenter, Randomized, Double-Blind Study of Risankizumab for the Treatment of Adult Subjects with Moderate to Severe Genital Psoriasis or Moderate to Severe Scalp Psoriasis No dispute reported 06/30/2026 1202534383
Principal investigator 1 ABBVIE INC. $1,529.40 12/31/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC DERMATOLOGY CENTER
A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata No dispute reported 06/30/2026 1202534385
Principal investigator 1 ABBVIE INC. $3,537.36 12/31/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC DERMATOLOGY CENTER
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy No dispute reported 06/30/2026 1202534387
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $16,159.50 12/18/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LL
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246432024
Principal investigator 1 ABBVIE INC. $1,582.10 12/04/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202527288
Principal investigator 1 ABBVIE INC. $2,408.00 12/04/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202527290
Principal investigator 1 ABBVIE INC. $3,536.25 12/04/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202527292
Principal investigator 1 Incyte Corporation $438.60 12/04/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240535182
Principal investigator 1 Incyte Corporation $718.50 12/04/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240535186
Principal investigator 1 Eli Lilly and Company $19,935.00 12/01/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION
Not supplied No dispute reported 06/30/2026 1187883280
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,978.02 12/01/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS RESEA
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289041
Principal investigator 1 Novartis Pharmaceuticals Corporation $24,822.54 11/15/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S No dispute reported 06/30/2026 1190302047
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $7,295.05 11/13/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LL
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246432021
Principal investigator 1 ABBVIE INC. $2,730.40 11/05/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202522171
Principal investigator 1 ABBVIE INC. $1,820.00 11/05/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202522173
Principal investigator 1 ABBVIE INC. $9,500.00 11/05/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC DERMATOLOGY CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202522175
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,705.44 10/22/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS RESEA
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287269
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $10,267.20 10/13/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LL
Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis No dispute reported 06/30/2026 1246432008
Principal investigator 1 ABBVIE INC. $1,352.00 10/09/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202516299
Principal investigator 1 ABBVIE INC. $5,396.25 10/09/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202516301
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $10,828.86 10/09/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LL
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246432016
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,197.47 09/26/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285999
Principal investigator 1 ABBVIE INC. $7,518.75 09/03/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202507499
Principal investigator 1 ABBVIE INC. $1,313.00 09/03/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202507501
Principal investigator 1 ABBVIE INC. $1,410.50 09/03/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202508184
Principal investigator 1 Janssen Research & Development, LLC $268.00 08/19/2025 Non-covered Recipient Entity
Fl Acdmc Centers Rsrch and Educ Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175189003
Principal investigator 1 Janssen Research & Development, LLC $3,993.00 08/19/2025 Non-covered Recipient Entity
Fl Acdmc Centers Rsrch and Educ Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175189119
Principal investigator 1 Incyte Corporation $318.60 08/14/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240535169
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $26,025.44 08/13/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LL
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246432013
Principal investigator 1 ABBVIE INC. $1,352.00 08/06/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202503261
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,978.02 08/01/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283693
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,645.94 08/01/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283695
Principal investigator 1 ABBVIE INC. $8,352.50 07/02/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202494855
Principal investigator 1 ABBVIE INC. $1,410.50 07/02/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202494857
Principal investigator 1 ABBVIE INC. $2,717.20 07/02/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202494859
Principal investigator 1 Incyte Corporation $2,016.00 06/24/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240535165
Principal investigator 1 Janssen Research & Development, LLC $3,021.00 06/13/2025 Non-covered Recipient Entity
Fl Acdmc Centers Rsrch and Educ Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175189079
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,958.28 06/13/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223281250
Principal investigator 1 Incyte Corporation $2,366.00 06/05/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240535160
Principal investigator 1 ABBVIE INC. $6,551.25 06/03/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202488135
Principal investigator 1 ABBVIE INC. $1,714.70 06/03/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202488233
Principal investigator 1 ABBVIE INC. $1,293.50 06/03/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202488235
Principal investigator 1 ABBVIE INC. $305.70 06/03/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202488237
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $204.95 05/27/2025 Non-covered Recipient Entity
Florida Academic Dermatology Center
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1235997369
Principal investigator 1 Incyte Corporation $318.60 05/08/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240535178
Principal investigator 1 ABBVIE INC. $2,730.40 05/07/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202483127
Principal investigator 1 ABBVIE INC. $5,558.75 05/06/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202481713
Principal investigator 1 Incyte Corporation $1,447.30 04/15/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240535173
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,555.00 04/11/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223277832
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,179.80 04/04/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LL
Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis No dispute reported 06/30/2026 1246432003
Principal investigator 1 ABBVIE INC. $7,466.25 04/03/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202473955
Principal investigator 1 Janssen Research & Development, LLC $6,122.00 03/21/2025 Non-covered Recipient Entity
Fl Acdmc Derm Ctrs
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175189134
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,215.46 03/21/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223276927
Principal investigator 1 ABBVIE INC. $4,462.50 03/07/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202459301
Principal investigator 1 ABBVIE INC. $3,798.60 03/07/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202459305
Principal investigator 1 ABBVIE INC. $1,608.10 03/07/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202459422
Principal investigator 1 ABBVIE INC. $1,943.50 03/07/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202459490
Principal investigator 1 ABBVIE INC. $1,174.40 03/06/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202456597
Principal investigator 1 Janssen Research & Development, LLC $2,169.00 03/03/2025 Non-covered Recipient Entity
Fl Acdmc Derm Ctrs
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175189141
Principal investigator 1 Janssen Research & Development, LLC $2,310.00 02/27/2025 Non-covered Recipient Entity
Fl Acdmc Centers Rsrch and Educ Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175189095
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,000.00 02/26/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223275591
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,642.00 02/25/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC
A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1190301635
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $32,323.00 02/12/2025 Non-covered Recipient Entity
Florida Academic Dermatology Center
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1235997367
Principal investigator 1 ABBVIE INC. $1,266.20 02/06/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202446787
Principal investigator 1 ABBVIE INC. $1,849.90 02/06/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202446861
Principal investigator 1 ABBVIE INC. $2,483.75 02/06/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202446866
Principal investigator 1 ABBVIE INC. $1,293.50 02/06/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202446887
Principal investigator 1 Janssen Research & Development, LLC $3,168.00 01/27/2025 Non-covered Recipient Entity
Fl Acdmc Centers Rsrch and Educ Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175189187
Principal investigator 1 Incyte Corporation $1,818.00 01/17/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240535191
Principal investigator 1 Incyte Corporation $2,129.40 01/07/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS RESEARCH AND EDUCATION LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240535195
Principal investigator 1 ABBVIE INC. $1,266.20 01/02/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202433457
Principal investigator 1 ABBVIE INC. $1,574.30 01/02/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202433462
Principal investigator 1 ABBVIE INC. $305.70 01/02/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202433489
Principal investigator 1 ABBVIE INC. $3,568.75 01/02/2025 Non-covered Recipient Entity
FLORIDA ACADEMIC CENTERS
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202433517